Long letter from Paul Hopper Exec Chairman re: how IMU is in the best shape its ever been and to keep patient re: share price: shorturl.at/rxLV5

I'll admit to feeling more confident for having read the letter in its entirety. I especially like IMU's invite to JPMorgan's prestigious Biotech conference next week, this should give more exposure. Letter also raises, but doesn't answer, questions about a major buyer involved (behind?) the recent 80M raise.

On page 1, a summary of IMU status/activity:

The fundamentals of your company:

• Approx $160m in the bank, which provides us with multiple years of funding runway and one of the strongest cash positions of any ASX biotech;

• Three distinct technology platforms: onCarlytics; Oncolytic viruses & B cell technologies;

• Five unique assets: onCARlytics (CF33-CD19), CHECKvacc (CF33-hNIS-PDL1), Vaxinia (CF33-hNIS), HER-Vaxx, PD1-Vaxx;

• Five clinical trials are currently ongoing;

• Four clinical trials to commence over 2023;

• Four FDA-approved INDs;

• One IND to be submitted in 2023;

• Ten disease areas;

• Three scientific collaborations;

• Two supply agreements with Roche and Merck KGaA/Pfizer.